Scinai Immunotherapeutics Ratios and Metrics

Market cap in millions ILS. Fiscal year is January - December.

Millions ILS. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar '26 Mar 24, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	7	10	9	36	135	104
Market Cap Growth	-37.53%	11.37%	-74.28%	-73.14%	29.69%	-67.74%
Enterprise Value	29	11	58	68	170	188
PS Ratio	1.90	4.34	-	-	-	-
PB Ratio	0.28	0.29	-0.57	-5.86	44.22	-7.13
P/TBV Ratio	0.98	0.66	-	-	44.22	-
EV/Sales Ratio	8.15	4.63	-	-	-	-
EV/EBITDA Ratio	-	-	-	-	-	21.29
EV/EBIT Ratio	-	-	-	-	-	25.66
Debt / Equity Ratio	0.30	0.21	-4.50	-12.24	29.52	-4.60
Debt / EBITDA Ratio	-	-	-	-	-	6.87
Net Debt / Equity Ratio	0.17	0.01	-3.43	-4.24	11.82	-3.96
Net Debt / EBITDA Ratio	-0.20	-0.02	-1.71	-0.71	-1.12	6.53
Net Debt / FCF Ratio	-0.24	-0.02	-1.57	-0.92	-1.53	-0.73
Asset Turnover	0.09	0.04	-	-	-	-
Quick Ratio	0.53	1.21	2.94	6.07	7.15	0.15
Current Ratio	0.71	1.32	3.06	6.15	7.30	0.17
Return on Equity (ROE)	1791.99%	177.37%	-	-	-	-
Return on Assets (ROA)	-39.55%	-34.92%	-27.24%	-23.39%	-26.97%	5.31%
Return on Capital Employed (ROCE)	-86.90%	-74.20%	-61.90%	-44.70%	-36.70%	-100.80%
Earnings Yield	15.90%	168.09%	-250.86%	-56.18%	-18.90%	-4.28%
FCF Yield	-261.46%	-222.45%	-386.66%	-78.52%	-17.42%	-75.55%
Buyback Yield / Dilution	-157.30%	-106.41%	-107.22%	-33.56%	-27.37%	-35.70%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.